Understand the source comparison
Comparative Evidence: Preclinical vs Clinical Data
The gap between animal models and human clinical trials is where most peptide therapies stall. BPC-157 has robust preclinical data across nerve crush injuries, diabetic neuropathy models, and chemotherapy-induced peripheral neuropathy (CIPN) in rodents. But ze
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The gap between animal models and human clinical trials is where most peptide therapies stall. BPC-157 has robust preclinical data across nerve crush injuries, diabetic neuropathy models, and chemotherapy-induced peripheral neuropathy (CIPN) in rodents. But zero completed Phase III trials in humans. Thymosin Beta-4 has advanced further, with a Phase II trial for acute myocardial infarction showing safety and some efficacy, but neuropathic pain applications remain investigational.
- Here's what separates promising research from clinical application: dosing extrapolation and administration route. Rodent studies use intraperitoneal or subcutaneous injections at doses of 10–100 micrograms per kilogram body weight. Translating that to a 70kg human suggests doses in the 0.7–7mg range. But bioavailability, half-life, and tissue distribution differ significantly between species. The peptides that show the most promise for nerve regeneration in controlled lab settings may require localized delivery (perineural injection) rather than systemic subcutaneous dosing to achieve therapeutic concentrations at the injury site in humans.
- Dihexa, a small-molecule peptidomimetic (not a true peptide), has shown cognitive enhancement and synaptogenesis in Alzheimer's models by activating hepatocyte growth factor (HGF) and its receptor c-Met. While not traditionally classified among the best peptides for nerve pain, its mechanism overlaps with nerve repair pathways. HGF promotes neurite outgrowth and Schwann cell proliferation, both critical for peripheral nerve regeneration. No human trials for neuropathic pain exist, but the compound's ability to cross the blood-brain barrier positions it as a candidate for central neuropathic pain conditions (post-stroke pain, spinal cord injury pain) where peripheral peptides may not reach therapeutic concentrations.
- BPC-157
- VEGF/FGF upregulation, NO stabilization
- Preclinical only (rodent nerve crush, diabetic neuropathy)
- Subcutaneous, intraperitoneal
- 14–28 days to measurable conduction velocity improvement
- Strongest preclinical nerve regeneration data; zero Phase III human trials
- Thymosin Beta-4
- Actin regulation, axonal sprouting
- Phase II cardiac trials (safety established); preclinical nerve injury models
- Subcutaneous
- 21–35 days to pain behavior reduction (von Frey testing)
- Safe in humans at tested doses; neuropathic pain use is investigational
- Cerebrolysin
- Neurotrophic factor mimicry (BDNF, NGF analogs)
- Phase III stroke trials; no neuropathic pain RCTs
- Intravenous (clinical use)
- Variable. Acute neuroprotection vs chronic regeneration timelines differ
- Crosses blood-brain barrier; evidence strongest for central nervous system injury
- Dihexa
- HGF/c-Met activation
- Preclinical Alzheimer's and synaptogenesis models only
- Oral, subcutaneous (animal studies)
- Unknown in nerve injury models
- Theoretical nerve repair potential via HGF pathway; no neuropathic pain data